Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | XDH | P47989 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | DPP4 | P27487 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hesperetin SCHEMBL6422865 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL5202121 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL29534477 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL29359052 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL39833 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL30696626 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL29484563 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL31689737 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL20929082 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL28595598 | 0.99 | CYP19A1 (0.98) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290514-A1 | An Antimicrobial Combination Composition Comprising Glycerol Derivatives and Bicyclic Compounds | SACHEM EUROPE B.V. (NL) | 2021-09-23 | — | — | US | claimed |
| CN-112955113-A | Antimicrobial binding compositions comprising glycerol derivatives and bicyclic compounds | 科莱恩国际有限公司 | 2021-06-11 | — | — | CN | claimed |
| EP-3817712-A1 | AN ANTIMICROBIAL COMBINATION COMPOSITION COMPRISING GLYCEROL DERIVATIVES AND BICYCLIC COMPOUNDS | Clariant International Ltd (CH) | 2021-05-12 | — | — | EP | claimed |
| WO-2020007571-A1 | AN ANTIMICROBIAL COMBINATION COMPOSITION COMPRISING GLYCEROL DERIVATIVES AND BICYCLIC COMPOUNDS | CLARIANT INTERNATIONAL LTD (CH) | 2020-01-09 | — | — | WO | claimed |
| US-20180042962-A1 | Vascular Calcification Prevention and Treatment | Summit Innovation Labs LLC (US) | 2018-02-15 | — | — | US | claimed |
| US-20170027902-A1 | Use of a Composition Comprising a Flavonol, A Flavonoid, and a Fatty Acid in the Treatment of Oxidative Injuries Due to Mitochondrial Dysfunction | ROBERTSON, GEORGE (CA) | 2017-02-02 | — | — | US | claimed |
| WO-2015154192-A1 | USE OF A COMPOSITION COMPRISING A FLAVONOL, A FLAVONOID, AND A FATTY ACID IN THE TREATMENT OF OXIDATIVE INJURIES DUE TO MITOCHONDRIAL DYSFUNCTION | ROBERTSON GEORGE (CA) | 2015-10-15 | — | — | WO | claimed |
| EP-0290442-A4 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. | CHEMEX PHARMACEUTICALS INC (US) | 1990-07-03 | — | — | EP | claimed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | claimed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | claimed |
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | claimed |
| US-4214963-A | Process for the preparation of substituted 4H-pyran-4-ones | Garcia de Lama, Javier (ES) | 1980-07-29 | — | — | US | claimed |
| US-20250312392-A1 | MICROBIAL COMPOSITIONS TO INCREASE THE PRODUCTION OF PCA FROM POLYPHENOLS | CHURCH & DWIGHT CO., INC. (US) | 2025-10-09 | — | — | US | disclosed |
| US-12364718-B2 | Microbial compositions to increase the production of PCA from polyphenols | CHURCH & DWIGHT CO., INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250114424-A1 | PLANT EXTRACT-BASED COMPOSITION AND ITS USE FOR TREATING GLUCOSE METABOLISM DISORDERS | ESSERRE PHARMA SRL (IT) | 2025-04-10 | — | — | US | disclosed |
| US-20250090435-A1 | PRESERVATIVES FOR COSMETIC AND PHARMACEUTICAL COMPOSITIONS | SACHEM, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | disclosed |
| EP-0065123-B1 | HARDLY SOLUBLE SALTS OF AMINOGLYCOSIDE ANTIBIOTICS | MERCK PATENT GmbH (DE) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290514-A1 | An Antimicrobial Combination Composition Comprising Glycerol Derivatives and Bicyclic Compounds | GK, MGLL, UGCG | CYP19A1 1248/4885CYP1A1 2314/4885CYP1A2 2206/4885 |
| US-20250090435-A1 | PRESERVATIVES FOR COSMETIC AND PHARMACEUTICAL COMPOSITIONS | PLOD2, CUTA, PHOSPHO1 | CYP19A1 49/4885CYP1A1 137/4885CYP1A2 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.